128 related articles for article (PubMed ID: 27185573)
1. Phase 1 study of dalotuzumab monotherapy and ridaforolimus-dalotuzumab combination therapy in paediatric patients with advanced solid tumours.
Frappaz D; Federico SM; Pearson AD; Gore L; Macy ME; DuBois SG; Aerts I; Iannone R; Geschwindt R; Van Schanke A; Wang R; Geoerger B
Eur J Cancer; 2016 Jul; 62():9-17. PubMed ID: 27185573
[TBL] [Abstract][Full Text] [Related]
2. A parallel-arm phase I trial of the humanised anti-IGF-1R antibody dalotuzumab in combination with the AKT inhibitor MK-2206, the mTOR inhibitor ridaforolimus, or the NOTCH inhibitor MK-0752, in patients with advanced solid tumours.
Brana I; Berger R; Golan T; Haluska P; Edenfield J; Fiorica J; Stephenson J; Martin LP; Westin S; Hanjani P; Jones MB; Almhanna K; Wenham RM; Sullivan DM; Dalton WS; Gunchenko A; Cheng JD; Siu LL; Gray JE
Br J Cancer; 2014 Nov; 111(10):1932-44. PubMed ID: 25290091
[TBL] [Abstract][Full Text] [Related]
3. A phase 1 study of oral ridaforolimus in pediatric patients with advanced solid tumors.
Pearson AD; Federico SM; Aerts I; Hargrave DR; DuBois SG; Iannone R; Geschwindt RD; Wang R; Haluska FG; Trippett TM; Geoerger B
Oncotarget; 2016 Dec; 7(51):84736-84747. PubMed ID: 27713169
[TBL] [Abstract][Full Text] [Related]
4. Combination of the mTOR inhibitor ridaforolimus and the anti-IGF1R monoclonal antibody dalotuzumab: preclinical characterization and phase I clinical trial.
Di Cosimo S; Sathyanarayanan S; Bendell JC; Cervantes A; Stein MN; Braña I; Roda D; Haines BB; Zhang T; Winter CG; Jha S; Xu Y; Frazier J; Klinghoffer RA; Leighton-Swayze A; Song Y; Ebbinghaus S; Baselga J
Clin Cancer Res; 2015 Jan; 21(1):49-59. PubMed ID: 25320355
[TBL] [Abstract][Full Text] [Related]
5. A phase II study of combined ridaforolimus and dalotuzumab compared with exemestane in patients with estrogen receptor-positive breast cancer.
Baselga J; Morales SM; Awada A; Blum JL; Tan AR; Ewertz M; Cortes J; Moy B; Ruddy KJ; Haddad T; Ciruelos EM; Vuylsteke P; Ebbinghaus S; Im E; Eaton L; Pathiraja K; Gause C; Mauro D; Jones MB; Rugo HS
Breast Cancer Res Treat; 2017 Jun; 163(3):535-544. PubMed ID: 28324268
[TBL] [Abstract][Full Text] [Related]
6. A multicenter, first-in-pediatrics, phase 1, pharmacokinetic and pharmacodynamic study of ridaforolimus in patients with refractory solid tumors.
Gore L; Trippett TM; Katzenstein HM; Boklan J; Narendran A; Smith A; Macy ME; Rolla K; ; Narashimhan N; Squillace RM; Turner CD; Haluska FG; Nieder M
Clin Cancer Res; 2013 Jul; 19(13):3649-58. PubMed ID: 23659969
[TBL] [Abstract][Full Text] [Related]
7. Phase I/IIa trial of the mammalian target of rapamycin inhibitor ridaforolimus (AP23573; MK-8669) administered orally in patients with refractory or advanced malignancies and sarcoma.
Mita MM; Poplin E; Britten CD; Tap WD; Rubin EH; Scott BB; Berk L; Rivera VM; Loewy JW; Dodion P; Haluska F; Sarantopoulos J; Mita A; Tolcher A
Ann Oncol; 2013 Apr; 24(4):1104-11. PubMed ID: 23211938
[TBL] [Abstract][Full Text] [Related]
8. A randomized phase II trial of ridaforolimus, dalotuzumab, and exemestane compared with ridaforolimus and exemestane in patients with advanced breast cancer.
Rugo HS; Trédan O; Ro J; Morales SM; Campone M; Musolino A; Afonso N; Ferreira M; Park KH; Cortes J; Tan AR; Blum JL; Eaton L; Gause CK; Wang Z; Im E; Mauro DJ; Jones MB; Denker A; Baselga J
Breast Cancer Res Treat; 2017 Oct; 165(3):601-609. PubMed ID: 28681171
[TBL] [Abstract][Full Text] [Related]
9. Phase IB study of the mTOR inhibitor ridaforolimus with capecitabine.
Perotti A; Locatelli A; Sessa C; Hess D; Viganò L; Capri G; Maur M; Cerny T; Cresta S; Rojo F; Albanell J; Marsoni S; Corradino I; Berk L; Rivera VM; Haluska F; Gianni L
J Clin Oncol; 2010 Oct; 28(30):4554-61. PubMed ID: 20855840
[TBL] [Abstract][Full Text] [Related]
10. Results of an international randomized phase III trial of the mammalian target of rapamycin inhibitor ridaforolimus versus placebo to control metastatic sarcomas in patients after benefit from prior chemotherapy.
Demetri GD; Chawla SP; Ray-Coquard I; Le Cesne A; Staddon AP; Milhem MM; Penel N; Riedel RF; Bui-Nguyen B; Cranmer LD; Reichardt P; Bompas E; Alcindor T; Rushing D; Song Y; Lee RM; Ebbinghaus S; Eid JE; Loewy JW; Haluska FG; Dodion PF; Blay JY
J Clin Oncol; 2013 Jul; 31(19):2485-92. PubMed ID: 23715582
[TBL] [Abstract][Full Text] [Related]
11. A phase I pharmacokinetic and pharmacodynamic study of dalotuzumab (MK-0646), an anti-insulin-like growth factor-1 receptor monoclonal antibody, in patients with advanced solid tumors.
Atzori F; Tabernero J; Cervantes A; Prudkin L; Andreu J; Rodríguez-Braun E; Domingo A; Guijarro J; Gamez C; Rodon J; Di Cosimo S; Brown H; Clark J; Hardwick JS; Beckman RA; Hanley WD; Hsu K; Calvo E; Roselló S; Langdon RB; Baselga J
Clin Cancer Res; 2011 Oct; 17(19):6304-12. PubMed ID: 21810918
[TBL] [Abstract][Full Text] [Related]
12. Phase II study of the mammalian target of rapamycin inhibitor ridaforolimus in patients with advanced bone and soft tissue sarcomas.
Chawla SP; Staddon AP; Baker LH; Schuetze SM; Tolcher AW; D'Amato GZ; Blay JY; Mita MM; Sankhala KK; Berk L; Rivera VM; Clackson T; Loewy JW; Haluska FG; Demetri GD
J Clin Oncol; 2012 Jan; 30(1):78-84. PubMed ID: 22067397
[TBL] [Abstract][Full Text] [Related]
13. Phase I study of the mTOR inhibitor ridaforolimus and the HDAC inhibitor vorinostat in advanced renal cell carcinoma and other solid tumors.
Zibelman M; Wong YN; Devarajan K; Malizzia L; Corrigan A; Olszanski AJ; Denlinger CS; Roethke SK; Tetzlaff CH; Plimack ER
Invest New Drugs; 2015 Oct; 33(5):1040-7. PubMed ID: 26091915
[TBL] [Abstract][Full Text] [Related]
14. Ridaforolimus: a promising drug in the treatment of soft-tissue sarcoma and other malignancies.
Dancey JE; Monzon J
Future Oncol; 2011 Jul; 7(7):827-39. PubMed ID: 21732754
[TBL] [Abstract][Full Text] [Related]
15. Results of a phase 1 trial combining ridaforolimus and MK-0752 in patients with advanced solid tumours.
Piha-Paul SA; Munster PN; Hollebecque A; Argilés G; Dajani O; Cheng JD; Wang R; Swift A; Tosolini A; Gupta S
Eur J Cancer; 2015 Sep; 51(14):1865-73. PubMed ID: 26199039
[TBL] [Abstract][Full Text] [Related]
16. Phase I study of temsirolimus in pediatric patients with recurrent/refractory solid tumors.
Spunt SL; Grupp SA; Vik TA; Santana VM; Greenblatt DJ; Clancy J; Berkenblit A; Krygowski M; Ananthakrishnan R; Boni JP; Gilbertson RJ
J Clin Oncol; 2011 Jul; 29(21):2933-40. PubMed ID: 21690471
[TBL] [Abstract][Full Text] [Related]
17. Phase I study of safety and tolerability of sunitinib in combination with sirolimus in patients with refractory solid malignancies and determination of VEGF (VEGF-A) and soluble VEGF-R2 (sVEGFR2) in plasma.
Li J; Kluger H; Devine L; Lee JJ; Kelly WK; Rink L; Saif MW
Cancer Chemother Pharmacol; 2016 Jun; 77(6):1193-200. PubMed ID: 27103123
[TBL] [Abstract][Full Text] [Related]
18. Ridaforolimus for patients with progressive or recurrent malignant glioma: a perisurgical, sequential, ascending-dose trial.
Reardon DA; Wen PY; Alfred Yung WK; Berk L; Narasimhan N; Turner CD; Clackson T; Rivera VM; Vogelbaum MA
Cancer Chemother Pharmacol; 2012 Apr; 69(4):849-60. PubMed ID: 22037923
[TBL] [Abstract][Full Text] [Related]
19. Combination mTOR and IGF-1R inhibition: phase I trial of everolimus and figitumumab in patients with advanced sarcomas and other solid tumors.
Quek R; Wang Q; Morgan JA; Shapiro GI; Butrynski JE; Ramaiya N; Huftalen T; Jederlinic N; Manola J; Wagner AJ; Demetri GD; George S
Clin Cancer Res; 2011 Feb; 17(4):871-9. PubMed ID: 21177764
[TBL] [Abstract][Full Text] [Related]
20. Phase I study for ridaforolimus, an oral mTOR inhibitor, in Japanese patients with advanced solid tumors.
Seki Y; Yamamoto N; Tamura Y; Goto Y; Shibata T; Tanioka M; Asahina H; Nokihara H; Yamada Y; Shimamoto T; Noguchi K; Tamura T
Cancer Chemother Pharmacol; 2012 Apr; 69(4):1099-105. PubMed ID: 22143378
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
